Document is current
Any future updates will be listed below
-
Authors
Paul, Devchand
Vukelja, Svetislava J.
Ann Holmes, Frankie http://orcid.org/0000-0001-8364-3906
Blum, Joanne L.
McIntyre, Kristi J.
Lindquist, Deborah L.
Osborne, Cynthia R.
Sanchez, Ines J.
Goldschmidt, Jerome H.
Wang, Yunfei
Asmar, Lina
Strauss, Lewis
O’Shaughnessy, Joyce
- License Information
-
More Information
Article History
Received: 21 January 2019
Accepted: 20 September 2019
First Online: 28 October 2019
Competing interests
: Drs. Paul, Vukelja, Holmes, Blum, McIntyre, Lindquist, Sanchez, Goldschmidt, Wang and Asmar reported no conflicts of interest. Dr. Osborne participated in advisory boards for Agendia and Guardant. Dr. Goldschmidt has received honoraria and speaker’s fees from Amgen, Eli Lilly, Bristol-Myers Squibb, and Genentech. Dr. O’Shaughnessy has been a consultant for Bristol-Myers Squibb, Agendia, Lilly, Novartis, Pfizer, Genentech, Roche, Merck, Odonate, Arch Oncology, CytomX, Genomic Health, Puma, Synthon, AstraZeneca, Abbvie, Nektar, Halozyme, Eisai, Celgene, Seattle Genetics, Amgen, Jounce, Pharmamar, Grail, 2X Oncology, Myriad, Biothera, Tempus, Oncomed, Carrick, Tocagen, Dompe, Kyoma Kirin, Loxo Oncology, Hengrui, Almac, Celldex, Immunomedics. Dr. Strauss is employed by and owns stock in Bristol-Myers Squibb.
